AAV-PHP.eB-Mediated Astrocytic IGFBPL1 Expression

Molecular Mechanism and Rationale

The AAV-PHP.eB-mediated delivery of IGFBPL1 to astrocytes leverages the neurotropic properties of engineered AAV capsids combined with GFAP (Glial Fibrillary Acidic Protein) promoter-driven specificity for astrocytic compartments in the central nervous system. This approach exploits astrocytes’ unique position as the most abundant glial cell type and their critical role in maintaining blood-brain barrier integrity, synaptic function, and neurometabolic coupling. IGFBPL1 expression in astrocytes would interface with distinct signaling networks compared to microglial targeting, particularly the astrocyte-specific glutamate-glutamine cycle, calcium wave propagation through connexin-mediated gap junctions, and neurovascular coupling mechanisms.

The molecular mechanism utilizes the same AAV-PHP.eB capsid BBB transcytosis properties but employs a GFAP promoter system that responds to astrocyte-specific transcription factors including STAT3, NFIB, and Sox9. Following astrocytic transduction, IGFBPL1 would modulate IGF signaling within the astrocytic syncytium, potentially enhancing neuroprotective factor secretion including BDNF, GDNF, and lactate production for neuronal metabolic support. The astrocytic IGFBPL1 would interact with aquaporin-4 (AQP4) water channels and Kir4.1 potassium channels, influencing glymphatic clearance and potassium buffering capacity. Additionally, IGFBPL1’s integrin-binding domains would interface with astrocytic endfeet at the blood-brain barrier, potentially modulating tight junction proteins including claudin-5 and occludin, thereby influencing BBB permeability and drug delivery efficiency.

Preclinical Evidence

AAV-PHP.eB demonstrates robust astrocytic transduction efficiency when coupled with GFAP promoters, achieving 70-80% astrocyte transduction rates in cortical and hippocampal regions following systemic administration. The astrocyte-specific expression pattern offers advantages for sustained transgene expression and widespread CNS distribution through the astrocytic syncytium, providing a complementary approach to microglial targeting for enhanced therapeutic drug delivery applications.